BML Capital Management LLC Has $1.34 Million Stock Position in Athira Pharma, Inc. $ATHA

BML Capital Management LLC lessened its position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) by 90.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 323,066 shares of the company’s stock after selling 2,907,601 shares during the quarter. Athira Pharma makes up approximately 1.0% of BML Capital Management LLC’s investment portfolio, making the stock its 13th largest holding. BML Capital Management LLC owned approximately 8.19% of Athira Pharma worth $1,337,000 at the end of the most recent reporting period.

Athira Pharma Stock Performance

Shares of NASDAQ ATHA opened at $5.56 on Monday. The company’s 50 day moving average price is $5.89 and its 200-day moving average price is $4.71. Athira Pharma, Inc. has a 52-week low of $2.20 and a 52-week high of $8.36. The company has a market capitalization of $21.93 million, a P/E ratio of -0.57 and a beta of 2.79.

About Athira Pharma

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.